Clarus Biologics, Inc.
Developer of a virus-like particle (VLP) vaccine/adjuvant platform intended to enhance immune activation, elicit mucosal and systemic antibody and T-cell responses, enable antigen-sparing, and support rapid deployment strategies. The company reports extensive pre-clinical testing across multiple species (including non-human primates), seeks cGMP clinical-grade production, and pursues licensing and commercialization pathways.
Industries
N/A
Nr. of Employees
medium (51-250)
Clarus Biologics, Inc.
5151 McCrimmon Parkway Suite 240, Morrisville, NC 27560, USA
Products
VLP-based vaccine adjuvant platform
A virus-like particle platform intended to be mixed with pathogen-specific antigens to increase innate activation and enhance antibody, T-cell and mucosal responses while enabling antigen dose reduction; reported extensive pre-clinical data including protection in challenge models.
VLP-based vaccine adjuvant platform
A virus-like particle platform intended to be mixed with pathogen-specific antigens to increase innate activation and enhance antibody, T-cell and mucosal responses while enabling antigen dose reduction; reported extensive pre-clinical data including protection in challenge models.
Expertise Areas
- Vaccine adjuvant development
- Pre-clinical vaccine evaluation
- Immunology and mucosal immunity
- Biologics platform development
Key Technologies
- Virus-like particles (VLP)
- Alphavirus-derived RNA platforms
- Mucosal immunity induction
- Antigen-sparing adjuvant approaches
News & Updates
Blog post describing a two-component vaccine strategy combining a non-specific VLP component with pathogen-specific antigen to replicate infection-like immune activation and enable rapid response and stockpiling.
Multiple pre-clinical studies reported elevated immune responses, increased protection on challenge, mucosal immunity, and no significant safety signals attributable to the VLP.
Company states the VLP adjuvant platform is covered by broad patent protection.
Blog post describing a two-component vaccine strategy combining a non-specific VLP component with pathogen-specific antigen to replicate infection-like immune activation and enable rapid response and stockpiling.
Multiple pre-clinical studies reported elevated immune responses, increased protection on challenge, mucosal immunity, and no significant safety signals attributable to the VLP.
Company states the VLP adjuvant platform is covered by broad patent protection.